Genedrive Share News (GDR)

Genedrive jumps on draft NICE testing guidance

(Sharecast News) - Point-of-care molecular diagnostics company Genedrive announced on Friday that the UK's National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of CYP2C19 genotyping before administering clopidogrel in the management of ischemic stroke (IS) patients.

Genedrive says NICE committee recommends CYP2C19 for stroke patients

(Alliance News) - Genedrive PLC on Friday said draft guidance from the UK's National Institute for Health & Care Excellence has recommended that CYP2C19 genotyping should be used to manage ischemic stroke patients.

AIM WINNERS & LOSERS: iEnergizer to depart; Unbound for sale

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Genedrive sees acceleration of revenue in 2023

Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Reports revenue in the six months to December 31 of GBP20,000 compared to nothing a year prior, and an operating loss of GBP2.7 million from GBP2.8 million. Confident that the company will see an acceleration of revenues through 2023 and going forwards. Agrees GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd with an initial drawn amount of GBP2 million, expected to be received in early April. Proceeds will be used towards the commercialisation of the antibiotic induced hearing loss test, Genedrive MT-RNR1 ID Kit and enhancing the Genedrive platform as well as providing additional working capital. Directors believe the facility is the best option available at present.

Genedrive MT-RNR1 ID kit receives final UK NICE recommendation for NHS

(Alliance News) - Genedrive PLC on Thursday said the UK National Institute for Health & Care Excellence ratified and finalised its recommendation that Genedrive's hearing loss gene screening test MT-RNR1 ID kit can be used by the NHS.

LONDON BRIEFING: Stocks add to rebound; SSE ups earnings guidance

(Alliance News) - Stocks in London are set to build on Wednesday's gains, as risk appetite recovers following the recent banking turmoil.

AIM WINNERS & LOSERS: Tribal shares drop on NTU contract termination

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Genedrive to roll out hearing loss screening in two NHS sites

(Alliance News) - Genedrive PLC on Monday reported further progress in the rollout of its hearing loss gene screening test in the UK.

LONDON MARKET OPEN: UBS down 15%, Credit Suisse down 60% after deal

(Alliance News) - Stock prices in London opened lower on Monday morning as the emergency takeover of beleaguered lender Credit Suisse over the weekend failed to quell market turmoil.

LONDON MARKET MIDDAY: Standard Chartered takeover talks lift FTSE 100

(Alliance News) - Stock prices in London were largely higher at midday on Thursday, thanks to a strong set of results from drug maker AstraZeneca and renewed takeover talks for lender Standard Chartered.

AIM WINNERS & LOSERS: Zytronic hit by electronic component shortages

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Genedrive hearing loss test recommended by UK health department body

(Alliance News) - Genedrive PLC on Thursday said the UK National Institute for Health & Care Excellence has preliminarily recommended its antibiotic hearing loss test, the MT-RNR1 ID kit.

LONDON MARKET OPEN: BAT falls on sales miss; Entain hit by MGM remark

(Alliance News) - Stock prices in London opened higher on Thursday, as investors digested a mixed set of UK company earnings.

AIM WINNERS & LOSERS: 88 Energy surges; Petro Matad plans fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.